Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.

Kerr C, Szmacinski H, Fisher ML, Nance B, Lakowicz JR, Akbar A, Keillor JW, Lok Wong T, Godoy-Ruiz R, Toth EA, Weber DJ, Eckert RL.

Oncogene. 2017 May 25;36(21):2981-2990. doi: 10.1038/onc.2016.452. Epub 2016 Dec 12.

2.

Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.

Lee J, Yakubov B, Ivan C, Jones DR, Caperell-Grant A, Fishel M, Cardenas H, Matei D.

Neoplasia. 2016 Nov;18(11):689-698. doi: 10.1016/j.neo.2016.09.003. Epub 2016 Oct 25.

3.

Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.

Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, Eckert RL.

Cancer Res. 2016 Dec 15;76(24):7265-7276. Epub 2016 Oct 25.

4.

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A.

Amino Acids. 2017 Mar;49(3):517-528. doi: 10.1007/s00726-016-2338-5. Epub 2016 Oct 19.

PMID:
27761756
5.

Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling.

Huang H, Chen Z, Ni X.

Exp Biol Med (Maywood). 2017 Jan;242(2):194-202. doi: 10.1177/1535370216670541. Epub 2016 Oct 4.

6.

Erratum to: Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: role in cancer cell migration.

Kumar A, Hu J, LaVoie HA, Walsh KB, DiPette DJ, Singh US.

BMC Cancer. 2016 Aug 8;16(1):609. No abstract available.

7.

Transglutaminase 3 protein modulates human esophageal cancer cell growth by targeting the NF-κB signaling pathway.

Li W, Zhang Z, Zhao W, Han N.

Oncol Rep. 2016 Sep;36(3):1723-30. doi: 10.3892/or.2016.4921. Epub 2016 Jul 8.

PMID:
27430245
8.

Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.

Wang X, Yu Z, Zhou Q, Wu X, Chen X, Li J, Zhu Z, Liu B, Su L.

Oncotarget. 2016 Feb 9;7(6):7066-79. doi: 10.18632/oncotarget.6883.

9.

Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells.

Oh K, Moon HG, Lee DS, Yoo YB.

Lab Anim Res. 2015 Dec;31(4):188-97. doi: 10.5625/lar.2015.31.4.188. Epub 2015 Dec 22.

10.

Transglutaminase 2 in cancer.

Huang L, Xu AM, Liu W.

Am J Cancer Res. 2015 Aug 15;5(9):2756-76. eCollection 2015.

11.

CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.

Min B, Park H, Lee S, Li Y, Choi JM, Lee JY, Kim J, Choi YD, Kwon YG, Lee HW, Bae SC, Yun CO, Chung KC.

Oncogene. 2016 Jul 14;35(28):3718-28. doi: 10.1038/onc.2015.439. Epub 2015 Nov 16.

PMID:
26568304
12.

Transglutaminase is a tumor cell and cancer stem cell survival factor.

Eckert RL, Fisher ML, Grun D, Adhikary G, Xu W, Kerr C.

Mol Carcinog. 2015 Oct;54(10):947-58. doi: 10.1002/mc.22375. Epub 2015 Aug 10. Review.

13.

Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Lee J, Condello S, Yakubov B, Emerson R, Caperell-Grant A, Hitomi K, Xie J, Matei D.

Clin Cancer Res. 2015 Oct 1;21(19):4482-93. doi: 10.1158/1078-0432.CCR-15-0226. Epub 2015 Jun 3.

14.

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.

Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL.

Oncotarget. 2015 Aug 21;6(24):20525-39.

15.

miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.

Cellura D, Pickard K, Quaratino S, Parker H, Strefford JC, Thomas GJ, Mitter R, Mirnezami AH, Peake NJ.

Mol Cancer Res. 2015 Jul;13(7):1095-1105. doi: 10.1158/1541-7786.MCR-14-0466. Epub 2015 May 1.

16.

The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.

Erdem S, Yegen G, Telci D, Yildiz I, Tefik T, Issever H, Kilicaslan I, Sanli O.

World J Urol. 2015 Oct;33(10):1553-60. doi: 10.1007/s00345-014-1462-7. Epub 2014 Dec 17.

PMID:
25515319
17.
18.

Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: role in cancer cell migration.

Kumar A, Hu J, LaVoie HA, Walsh KB, DiPette DJ, Singh US.

BMC Cancer. 2014 Apr 11;14:256. doi: 10.1186/1471-2407-14-256. Erratum in: BMC Cancer. 2016;16(1):609.

19.

Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Jiang WG, Ye L, Sanders AJ, Ruge F, Kynaston HG, Ablin RJ, Mason MD.

J Transl Med. 2013 Oct 25;11:269. doi: 10.1186/1479-5876-11-269.

20.

Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer.

Yang LL, Liang CY, Lu TC, Zhi CY, Liu B, Zhou JH, Liu XM, Gao HC, Huang W.

Mol Med Rep. 2013 Dec;8(6):1812-6. doi: 10.3892/mmr.2013.1706. Epub 2013 Sep 27.

PMID:
24085483

Supplemental Content

Loading ...
Support Center